WGBS for iPSC Cell Therapy Safety Assessment
WGBS for iPSC Cell Therapy Safety Assessment
1. Background
1.1 Core Positioning
WGBS (Whole Genome Bisulfite Sequencing), with its unique technical advantages of single-base resolution and whole-genome coverage, provides epigenetic quality control for iPSC-derived cell therapy products that meets regulatory requirements. It is applicable to comprehensive epigenetic safety assessment of iPSC-derived cell therapy products including cardiomyocytes, neurons, retinal pigment epithelial cells, β cells, NK cells, and more.
1.2 Clinical Translation Progress of iPSC Cell Therapy Products
Induced pluripotent stem cell (iPSC)-derived cell therapy products have entered a fast track for clinical translation. Multiple iPSC-derived products have entered clinical trials globally, including:
(1) iPSC-derived retinal pigment epithelial cells (RPE) for macular degeneration
(2) iPSC-derived cardiomyocytes for heart failure
(3) iPSC-derived dopaminergic neurons for Parkinson's disease
(4) iPSC-derived NK cells/CAR-NK cells for cancer
(5) iPSC-derived β cells for diabetes
1.3 Unique Epigenetic Challenges Facing iPSC Products
iPSC products face three categories of critical epigenetic safety challenges that may affect product quality, safety, and clinical efficacy:
(1) Challenge 1: Epigenetic Memory
A landmark Nature (2010) study first demonstrated that low-passage iPSCs retain DNA methylation signatures from donor tissue of origin. This "epigenetic memory" can affect the differentiation potential and functional homogeneity of cells.
Memory Type | Manifestation | Detection Requirement |
Residual donor cell methylation | Donor-specific methylation patterns from fibroblasts/blood cells not fully erased | Genome-wide methylation profile comparison |
Tissue-specific gene regulation | Methylation status of tissue-specific enhancers | In-depth enhancer region analysis |
Differentiation bias | Epigenetic state of lineage genes related to donor tissue | Lineage-specific locus quantification |
(2) Challenge 2: Reprogramming-Induced Aberrant Methylation (De novo Aberrant DMRs)
The reprogramming process not only fails to fully erase donor cell methylation imprints but also introduces novel aberrantly methylated regions in iPSCs. Studies show that 88% of hypermethylated DMRs can be transmitted to terminally differentiated cells, potentially affecting the differentiation capacity of iPSCs and the function of differentiated products.
DMR Type | Characteristics | Risk |
iPSC-specific hypermethylated DMRs | Regions unmethylated in ESCs but aberrantly hypermethylated in iPSCs | May affect pluripotency gene expression |
CpG island shore methylation anomalies | Aberrant methylation in flanking regions of CpG islands | Affects regulation of neighboring genes |
Mega-DMRs | Large-scale (>10 kb) aberrantly methylated regions | May affect 3D chromatin architecture |
(3)Challenge 3: Imprinted Gene Methylation Abnormalities
The expression of imprinted genes depends on parent-of-origin-specific DNA methylation patterns. iPSC reprogramming and prolonged culture may lead to methylation loss or aberrant gain at imprinting control regions (ICRs), causing imprinting defects associated with tumorigenesis and developmental abnormalities.
Imprinted Gene/Region | Normal Methylation Status | Consequences of Abnormality |
H19/IGF2 | Paternal methylation | Overgrowth, tumor risk |
SNRPN/UBE3A | Maternal methylation | Prader-Willi/Angelman syndrome-like phenotype |
DLK1/MEG3 | Paternal methylation | Developmental abnormalities |
Zrsr1 | Maternal methylation | Associated with reduced iPSC pluripotency |
2. WGBS Detection Principle
2.1 Why iPSC Products Must Undergo WGBS Testing
Epigenetic quality control of iPSC products requires genome-wide level assessment for the following reasons:
(1) Epigenetic memory, aberrant DMRs, and imprinted gene defects may occur at any position in the genome.
(2) The limited coverage of RRBS and methylation arrays may miss critical aberrantly methylated regions.
(3) Regulatory agencies require comprehensive epigenetic characterization data to support IND/BLA submissions.
(4) Only WGBS can provide a genome-wide DNA methylation profile at single-base resolution.
WGBS is the only technology capable of comprehensively assessing the epigenetic quality of iPSC products:
Detection Method | Coverage | Discovery Capability | Applicability |
WGBS | >90% CpG sites | ✓ Can detect unpredicted aberrant sites | Gold standard for iPSC product quality control |
RRBS | 5–10% CpG sites | Limited, covers only CpG-enriched regions | Preliminary screening |
Methylation array | 2–3% preset sites | ✗ Cannot identify novel sites | Not applicable |
2.2 WGBS Technical Advantages
Why is WGBS the gold standard for epigenetic quality control of iPSC products?
Technical Parameter | WGBS | RRBS | Methylation Array | Advantage |
CpG Coverage | >90% (~28 million sites) | 5–10% | 2–3% | Comprehensive detection of unknown risks |
Resolution | Single-base | Single-base | Probe sites | Precise boundary localization |
Novel Discovery | ✓ | Limited | ✗ | Essential for aberrant DMR detection |
Imprinted gene coverage | ✓ Complete coverage of all ICRs | Partial coverage | Preset probes | Critical for imprinting integrity assessment |
Key Conclusion:For iPSC products: Only WGBS can comprehensively assess epigenetic memory, aberrant DMRs, and imprinted gene integrity — these constitute the Critical Quality Attributes (CQA) required by regulatory agencies.
2.3 WGBS Technical Principle
The core of WGBS is the use of bisulfite chemical conversion to achieve single-base discrimination between methylated and unmethylated cytosines. Combined with high-throughput sequencing and bioinformatic analysis, it constructs a genome-wide single-base resolution DNA methylation profile. The overall workflow encompasses the following key steps: sample pre-processing, DNA extraction and library construction, bisulfite chemical conversion, high-throughput sequencing, and bioinformatic analysis with methylation identification.
Figure 1. WGBS detection technology workflow
3. Technology Innovation and Advantages
3.1 Optimized Library Construction and Sequencing Strategy
(1) Technical Optimization for iPSC Samples
Technical Step | Optimization Strategy | Advantage |
DNA extraction | Optimized for different cell types (iPSC, cardiomyocytes, neurons, etc.) | Maximizes high-quality DNA yield |
Fragmentation | Covaris sonication with precise control (200–300 bp peak) | Ensures fragment uniformity, improves coverage homogeneity |
Adapter ligation | Pre-methylated adapters | Prevents adapter loss during bisulfite conversion |
Bisulfite conversion | Optimized temperature, time, and reagent concentration | >99.5% conversion efficiency |
Amplification strategy | Low-cycle high-fidelity PCR | Reduces amplification bias, ensures quantitative accuracy |
(2) Sequencing Depth Selection Guide
Application Scenario | Recommended Depth | CpG Coverage | Data Volume (Human Genome) |
Comprehensive IND/BLA submission-grade assessment | 30–40X | >90% | 120–160 GB |
MCB/WCB characterization | 30X | >85% | 100–120 GB |
Clone screening / stability studies | 20–30X | >80% | 80–100 GB |
Batch release / routine QC | 15–20X | >75% | 60–80 GB |
3.2 Professional Bioinformatics Analysis Pipeline
(1) Standard Analysis Modules
Module | Analysis Content | Output |
Data QC | Sequencing quality, conversion efficiency, coverage depth, duplication rate | QC report |
Alignment & Quantification | Bismark alignment, CpG/CHG/CHH methylation quantification | Methylation matrix |
Global Analysis | Chromosomal distribution, functional element classification statistics | Global methylation profile |
DMR Analysis | Differentially methylated region identification, statistical testing, effect size evaluation | DMR list and annotation |
Functional Annotation | Gene, enhancer, CpG island, imprinting region annotation | Functional annotation report |
(2) iPSC Product-Dedicated Analysis
Dedicated Module | Analysis Content |
Epigenetic memory assessment | Quantification of donor tissue-specific methylation retention |
Reprogramming quality scoring | Methylation similarity to ESC reference, pluripotency locus analysis |
Aberrant DMR screening | Identification of iPSC-specific aberrantly methylated regions |
Imprinted gene integrity | Methylation status check of key ICRs |
Differentiation state assessment | Lineage-specific vs. pluripotency locus methylation |
4. Application Scenarios and Testing Plans
4.1 Detection Timing and Sample Design
Epigenetic quality control of iPSC products should span the entire manufacturing workflow, from donor cells to the final differentiated product:
Detection Checkpoint | Sample Type | Recommended Depth | Detection Purpose |
Donor cell characterization | Donor fibroblasts/PBMCs | 20–30X | Establish donor-specific methylation baseline |
Post-reprogramming clone screening | Multiple independent iPSC clones | 30X | Select clones with optimal epigenetic quality |
Master Cell Bank (MCB) establishment | iPSC batch designated for banking | 30–40X | Comprehensive epigenetic characterization |
Differentiated final product characterization | Target differentiated cells | 30X | Assess epigenetic status post-differentiation |
Stability studies | Samples at different passages / post-cryopreservation | 20–30X | Epigenetic stability assessment |
4.2 Core Analysis Content
(1) Pluripotency-Related Methylation Assessment
Pluripotency marker gene promoter analysis:
Gene | Expected Status (iPSC) | Analysis Content |
OCT4 (POU5F1) | Demethylated, activated | Promoter methylation level |
SOX2 | Demethylated, activated | Promoter methylation level |
NANOG | Demethylated, activated | Promoter methylation level |
REX1 | Demethylated, activated | Promoter methylation level |
(2) Epigenetic Memory Assessment
Donor tissue-specific methylation retention analysis:
1. Genome-wide DMR analysis: donor cells vs. iPSCs
2. Changes in methylation status of tissue-specific gene promoters
3. Degree of methylation erasure at lineage-specific enhancers
4. Similarity score comparison against ESC reference
(3) Reprogramming Quality Assessment
Genome-wide methylation comparison against ESC reference:
Analysis Content | Expected Result | Aberrant Signal |
Global methylation level | Similar to ESC (~80% CpG methylation) | Significant deviation from ESC |
Promoter methylation | Low methylation at active gene promoters | Aberrant hypermethylation |
Gene body methylation | High methylation in actively transcribed gene bodies | Aberrant hypomethylation |
Repeat element methylation | High methylation at LINE/SINE elements | Aberrant demethylation (genomic instability signal) |
(4) Imprinted Gene Integrity Analysis
Methylation quantification at key imprinting control regions (ICRs):
1. Methylation status of known human imprinted regions (>100 regions)
2. Allele-specific methylation analysis (requires high depth or combined SNP analysis)
3. Functional impact assessment of aberrant imprinting loci
(5) Epigenetic Assessment of Differentiated Final Products
Analysis Content | Detection Purpose |
Lineage-specific gene activation | Demethylation of target cell-type marker gene promoters |
Pluripotency gene silencing | Re-methylation of OCT4, NANOG, and other promoters |
Non-target lineage gene silencing | Hypermethylation of non-target lineage gene promoters |
Residual undifferentiated cell detection | Methylation levels at pluripotency-associated loci |
5. Regulatory Support and Service Contents
5.1 FDA Regulatory Framework
According to FDA and ICH guidelines, the CMC (Chemistry, Manufacturing and Controls) section for iPSC-derived cell therapy products requires comprehensive product characterization. FDA expectations for epigenetic characterization of iPSC products:
Assessment Type | Specific Requirement | WGBS Application |
Identity | Confirm the epigenetic identity of iPSC/differentiated cells | Methylation fingerprinting |
Purity assessment | Detect residual undifferentiated or non-target cells | Pluripotency/lineage-specific locus methylation |
Safety assessment | Evaluate epigenetic anomalies associated with tumorigenesis risk | Oncogene/tumor suppressor gene methylation status |
Potency/Function | Correlate epigenetic status with cellular function | Functional gene methylation analysis |
Stability | Demonstrate epigenetic stability across passages/cryopreservation | Multi-timepoint/inter-batch comparison |
5.2 CDE/NMPA Regulatory Requirements
China's CDE "Technical Guidance Principles for Clinical Trials of Human Stem Cell-Derived and Derived Cell Therapy Products (Trial)" explicitly requires:
(1) For stem cell products subjected to complex in vitro manipulation, it is recommended to assess genetic and epigenetic stability at appropriate stages.
(2) For pluripotent stem cell-derived products, genome-wide epigenomic analysis is recommended to assess risk.
(3) Integration of karyotyping with genome-wide level detection methods for quality control is encouraged.
5.3 Regulatory Submission Support
Data Package Meeting IND/BLA Submission Requirements
Component | Content Description | Format |
Technical report | Methodology description, method validation, QC standards | PDF/Word |
Analysis report | Comprehensive analysis results, data interpretation, safety assessment conclusion | PDF/Word |
Raw data | FASTQ files, alignment files | Electronic data package |
Processed data | Methylation matrix, DMR list, annotation files | Electronic data package |
Professional Technical Support Services
(1) Project design consultation: Design optimal testing plans based on product type and regulatory requirements
(2) Sample strategy recommendations: Scientific design of sample types, quantities, and time points
(3) Data interpretation support: Assist in interpreting the biological and regulatory significance of analysis results
(4) Regulatory inquiry support: Assist in preparing responses to technical inquiries from regulatory agencies
(5) Multi-omics integration: Can be combined with RNA-seq, ATAC-seq, ChIP-seq, and other data for integrated analysis
6. Sample Requirements
DNA Sample Standards
Parameter | Standard Requirement | IND/BLA Submission Grade | Notes |
Total DNA amount | ≥3 μg | ≥5 μg | Higher depth sequencing requires more |
DNA concentration | ≥50 ng/μL | ≥100 ng/μL | — |
Purity (OD260/280) | 1.8–2.0 | 1.8–2.0 | Protein contamination affects conversion |
Integrity | Main band >10 kb | Main band >15 kb | Degradation affects data quality |
Cell / Tissue Samples (DNA Extraction Service Available)
Sample Type | Recommended Amount | Notes |
iPSC | ≥5×10⁶ cells | Avoid differentiated state |
Differentiated cells | ≥5×10⁶ cells | Specify differentiation status and purity |
Primary cells | ≥1×10⁷ cells | Minimize culture time |
Tissue samples | ≥100 mg | Stored at −80°C, avoid repeated freeze-thaw cycles |
① All samples must meet the above quality standards to ensure accuracy and reliability of test results. ② For special sample types, please contact the GeneRulor technical team in advance (Tel: 400-6309596; Product ordering/technical support: service@generulor.com).
7. References
1. Kim K, et al. Epigenetic memory in induced pluripotent stem cells. Nature. 2010;467(7313):285-290.
2. Polo JM, et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol. 2010;28(8):848-855.
3. Lister R, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature. 2009;462(7271):315-322.
4. Jha BS, et al. Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product. STEM CELLS Transl Med. 2021;10(2):198-208.
5. Kaneko S, et al. Considerations for the development of iPSC-derived cell therapies: a review of key challenges by the JSRM-6. ISCT iPSC Committee. Cytotherapy. 2024;26(9):913-927.
CDE/NMPA. Technical Guidance Principles for Clinical Trials of Human Stem Cell-Derived and Derived Cell Therapy Products (Trial). 2023.
![Micromessenger Scan to consult](javascript:Site.hoverQrCode("//33974620.s21i.faiusr.com/2/ABUIABACGAAg9by4zQYo7oak_wUwxwY40QY.jpg",this,{"tips":"请使用微信扫一扫"});){kind=link}
![Linkedin LIN HUABING](javascript:Site.hoverQrCode("//33974620.s21i.faiusr.com/4/ABUIABAEGAAgloWpzgYo0eeGgAUwhgQ4igQ.png",this,{"tips":"Scan QR code"});){kind=link}